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The mechanisms behind hot ﬂashes in menopausal women are not fully understood. The ﬂashes in women are probably preceded
by and actually initiated by a sudden downward shift in the set point for the core body temperature in the thermoregulatory center
that is aﬀected by sex steroids, β-endorphins, and other central neurotransmitters. Treatments that inﬂuence these factors may be
expected to reduce hot ﬂashes. Since therapy with sex steroids for hot ﬂashes has appeared to cause a number of side eﬀects and
risks and women with hot ﬂashes and breast cancer as well as men with prostate cancer and hot ﬂashes are prevented from sex
steroid therapy there is a great need for alternative therapies. Acupuncture aﬀecting the opioid system has been suggested as an
alternative treatment option for hot ﬂashes in menopausal women and castrated men. The heat loss during hot ﬂashes may be
mediated by the potent vasodilator and sweat gland activator calcitonin gene-related peptide (CGRP) the concentration of which
increases in plasma during ﬂashes in menopausal women and, according to one study, in castrated men with ﬂushes. There is also
evidence for connections between the opioid system and the release of CGRP. In this paper we discuss acupuncture as a treatment
alternative for hot ﬂashes and the role of CGRP in this context.
1.Introduction
Hot ﬂashes are classic menopausal symptoms in women [1,
2].However,ﬂashesarealsoreportedby43–77%ofmenafter
castration therapy [3–5], and they usually persist for many
years and may impair quality of life [4]. Night sweats can be
severe enough to cause sleep disturbance. In addition, hot
ﬂashes can be associated with anxiety, nausea, tachycardia,
and tachypnea, as well as pressure in the head and chest. Hot
ﬂashes also occur in men with testicular insuﬃciency and in
“normal aging men,” but to a lesser extent [6, 7]. Nearly all
reported ﬂashes in women and men after castration therapy
are also objectively conﬁrmed by increased cutaneous blood
ﬂow, skin conductance, and/or skin-temperature [8–11].
The physiology of hot ﬂashes is not known in detail, but
probably involves the core body temperature, neuromodula-
tors,andperipheralvasculatureandsweatglands.Vasomotor
symptoms have been shown to correlate with the decrease
in estrogen production during the menopausal transition
and with testosterone decreases after castration therapy with
orchiectomy or GnRH Analogues in men with prostate
cancer. Estrogens, testosterone, and also other hormones are
potent neuromodulators of the central nervous system [12].
Freedman and Subramanian have demonstrated that women
with hot ﬂashes have an increased core temperature and a
reduced thermoneutral zone compared with women without
ﬂashes [13]. It is possible that ﬂuctuations in estrogen
concentrations cause changes in other hormones or neuro-
transmitters in the central nervous system that lead to an
alterationincoretemperatureandanarrowerthermoneutral
zone in women predisposed to hot ﬂashes [14]. A narrow
thermoneutral zone causes reactions that lower central body
temperature when the actual central temperature reaches or
exceeds the upper limit of the neutral zone. Such reactions
are vasodilation causing increased blood ﬂow in the upper
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to the surrounding environment and activation of sweat
glands, which leads to energy loss by evaporation. Another
theory is that decreased endogenous estrogen concentrations
also decrease hypothalamic β-endorphins that lead to an
instability in the hypothalamic thermoregulatory centre [15,
16]. When the set point in the thermoregulatory center is
suddenly lowered, reactions are initiated that decrease body
temperature, acting in the same way as when the upper
limit of the thermoneutral zone is exceeded. We suggest
that testosterone plays a role in men similar to the role
played by estrogen in women in this context and thus when
testosterone concentrations are lowered as they are after
castration therapy, thermoregulation becomes less stable.
The relationship between serotonin and temperature
control has long been recognized. Probably both nora-
drenalin and serotonin may aﬀect the risk of hot ﬂushes
via a narrowed thermoneutral zone [13]. Serum levels of
serotonin are lower in postmenopausal women than the
levels found before menopause, and estrogen therapy has
been shown to normalize these levels. Estrogen withdrawal
causes a reduction in circulating serotonin, resulting in an
upregulation of the 5-HT2A receptor in the hypothalamus
[17]. It has thus been suggested that both the concentrations
ofβ-endorphinsandserotonininthehypothalamusdecrease
with decreasing estrogen concentration [18]. The reduced β-
endorphin and serotonin concentrations increase the release
of noradrenaline, and this may in turn cause sudden
drops in the set point in the thermoregulatory centre in
the hypothalamus and elicit inappropriate heat loss [18–
21]. According to this hypothesis, any intervention that
increasesestrogen,β-endorphin,orserotoninconcentrations
or decreases noradrenalin levels may be expected to reduce
hot ﬂashes.
The heat loss during the hot ﬂash and sweating seems
to be achieved by activation of cholinergic sweat glands
and vasodilation of the skin, and these reactions may be
mediated by the potent vasodilator calcitonin gene-related
peptide (CGRP) [22]. Endogenous opioids modulate the
release of the potent endothelium-dependent vasodilator
CGRP at the spinal cord level [23, 24]. When CGRP is
administrated intravenously to healthy male volunteers, it
produces symptoms very similar to hot ﬂashes, with a dose-
dependent increase in cutaneous blood ﬂow [25]. CGRP
has been found to increase in plasma during hot ﬂashes in
postmenopausal women [26–29] and also, according to one
study, in men with ﬂashes who had been castrated due to
carcinoma of the prostate [11]. Urinary excretion of CGRP
over 24h is higher in ﬂashing postmenopausal women than
in postmenopausal women without hot ﬂashes, and in a
group of postmenopausal women with hot ﬂashes CGRP in
24h urine decreased signiﬁcantly after 12 weeks of successful
treatment with acupuncture [30].
2.TreatmentofHotFlashes
The gold standard for treating hot ﬂashes is estrogen therapy
[12] which reduces the frequency and severity of hot ﬂashes
by 75% percent compared to placebo according to a meta-
analysis from the Cochrane Database System [31]. Since
hormonal treatment is at present controversial, largely as
a result of results like those from the HERS study and
the WHI study, there is a need for other nonhormonal
treatment alternatives [32, 33]. Findings from these and
other studies have led to more restrictive recommendations
from the authorities on the use of estrogens and substan-
tially decreased the use of hormone therapy. Therefore,
many women today have climacteric symptoms including
ﬂashes but abstain from hormone replacement therapy.
Furthermore, numerous women with breast cancer and
men with prostate cancer have troublesome hot ﬂashes but
should not use sex steroid therapy because of the risk of
cancer recurrence. As pointed out by, for example, Borrelli
and Ernst, the potential serious side eﬀects from hormone
replacement therapy cause a great need for alternative and
complementary treatments of hot ﬂashes [34].
Progestagens have been shown to reduce hot ﬂashes by
80–90% [35, 36], but their side eﬀects include weight gain,
ﬂuid retention, and mastalgia [35] and should not be given
to women with breast cancer.
Tibolone, a synthetic hormone that acts on sex hormone
receptors, has also been shown to be as eﬀective as estrogen
therapy for treating hot ﬂashes [37, 38]. Tibolone, however,
should not be used in women who have had breast cancer
because of the risk of recurrence and because it causes other
side eﬀects similar to those caused by estrogens [39].
Clonidine,selectiveserotoninreuptakeinhibitors(SSRI),
and gabapentin may decrease the frequency of hot ﬂushes
and the distress caused by them. The use of phytoestrogens
and black cohorsh showed mixed results. The mechanism
of action of SSRIs is thought to involve increased serotonin
levels and thereby less severe vasomotor symptoms [40].
SSRIs reduce hot ﬂashes by up to 50–60% compared to 80%
reduction in women using estrogen [41]. However, recent
data suggest that at least some SSRIs are associated with an
increased risk of death from breast cancer, probably because
SSRIs inhibit cytochrome P450 2DG (CYP2D6), which is
necessary for the metabolism of tamoxifen, thus reducing
the eﬀect of the tamoxifen given to many women as part of
treatment for breast cancer. Paroxetine is the one SSRI that is
the strongest inhibitor of CYP2D6 and should therefore not
be given to women with breast cancer [42].
Venlafaxine is the SSRI most frequently prescribed as
an alternative to estrogens for the treatment of climacteric
symptoms. In addition to its function asan SSRI, venlafaxine
also acts as a noradrenergic reuptake inhibitor and is
therefore called serotonin-noradrenaline reuptake inhibitor
(SNRI). It is the most frequently prescribed alternative to
estrogens [41] and halves the severity of hot ﬂashes. Even if
the eﬀect is signiﬁcant, it is only marginally better than the
eﬀect of placebo [43].
Lifestyle factors seem also to contribute to strengthening
climacteric symptoms; greater BMI is a risk factor for hot
ﬂashes, as are smoking and high consumption of caﬀeine
and alcohol [44]. Weight loss, regular exercise, and smoking
cessation have also been recommended in order to decrease
hot ﬂashes. The eﬃcacy of these recommendations has notEvidence-Based Complementary and Alternative Medicine 3
been demonstrated, however, because of lack of suﬃcient
clinical trials according to the Cochrane Database System
Review [12, 45]. Physically active postmenopausal women
have a lower occurrence of vasomotor symptoms, perhaps
due to a higher central opioid activity [46, 47]. Acupuncture
also seems to be eﬀective in reducing the intensity and
f r e q u e n c yo fh o tﬂ a s h e si nw o m e na n di nm e nd e p r i v e do f
sex steroids due to prostate cancer [22, 48–53].
3.Acupuncture
Acupuncture is known as one of the oldest healing systems
in the world and is a part of traditional chinese medicine
(TCM). Variants of TCM acupuncture, based on the old
Taoist theories of Yin and Yang and Qi, are practiced
throughout the Western World today [54]. The physiological
processes involved in acupuncture treatment are not fully
known, but factors of importance may include changes
in autonomic nerve functioning [55–57]a n dm a ya ﬀect
hormones such as cortisol [58, 59], oxytocin [60, 61],
neuropeptides as β-endorphin [62], serotonin [63, 64],
and cytokines [65–67]a n da l t e r a t i o n si nc o l l a g e nn e t w o r k
communication [68, 69]. Acupuncture probably aﬀects
serotonin and noradrenalin activity in the central nervous
system [70, 71], and thus has the potential to inﬂuence
the thermoregulatory centre, making it more stable [22].
Acupuncture may also have peripheral eﬀects and cause
the release of substance P, vasoactive intestinal peptide, and
CGRP [72–74]. Probably the eﬀects of acupuncture are
causedbymulticomponent,complexinterventions.Insham-
controlled studies, attempts are frequently made to control
the needling eﬀect by controlling the location, insertion
depth, stimulation, needle size, and number. However, sev-
eral other potentially therapeutic acupuncture-speciﬁc com-
ponents may be present in the control group; these include
nonspeciﬁc components (time, attention, credibility, and
expectation) and speciﬁc non-needling components such
as psychological history, diagnosis, and education and also
physiological events like palpation and moxibustion [75].
One of the traditional forms of acupuncture is manual
acupuncture (MA), where the needles are inserted in the
speciﬁc acupuncture points, according to TCM. Often the
needles are twirled to evoke the DeQui sensation, charac-
terised by a distinct sensation of distension and numbness
[62]. The DeQui sensation is believed to activate A-delta
ﬁbers from free nerve endings in the skin or from high-
threshold ergoreceptors in the muscle. Electroacupuncture
(EA) is derived from MA, with the addition of electric
stimulation applied to one or two pairs of the needles,
either applied with a high (80–100Hz) or low frequency
(2Hz). EA has been shown to be more powerful than MA
in studies on pain treatment [76, 77]. This stimulation is
believed to activate peripheral nerve endings, muscles, and
also connective tissue. The nerve stimulation causes aﬀerent
signals, which increase, for example, central β-endorphins,
and serotonin and probably also activate receptors [78–80].
3.1. Acupuncture and Hot Flashes. Acupuncture has been
tried for hot ﬂashes since it seems to increase central
β-endorphin activity [62], which would as a result make
thermoregulation more stable and in turn decrease vaso-
motor symptoms [81, 82]. Some studies have shown a
decreased activity, measured by fMRI, in the amygdala and
hypothalamus, when acupuncture is given [83]. It may be
speculated that during an incident of hot ﬂashes there is
a high neuronal activity in the hypothalamus and that
acupuncture may reduce this activity, perhaps mediated by
increased β-endorphin release and decreased noradrenalin
activity.
Acupuncture has been found to decrease the number of
hotﬂashesbyatleast50%butdoesnotseemtobeaseﬀective
as estrogen therapy [84]. EA has been associated with a
decreasednumberandintensityofhotﬂashesinmenopausal
women, both with and without breast cancer [22, 49–52],
and also in men treated by castration due to prostate cancer
[48, 53]. While pharmacological studies often use “placebo
pills” for treatment of the control groups, it has been more
problematic to ﬁnd a credible but still inert sham technique
thatmaybeusedinacupuncturestudies.Severaldeviceshave
been tried [85, 86], but these methods do not seem to be
totally without eﬀect, probably because they cause neuronal
stimulation attributable to local pressure on or beside
acupuncture points and induce tactile neuronal stimulation
[87, 88]. Earlier studies have shown a better eﬀect of EA
on pain in lateral epicondylalgia [77] and low back pain
[76]thanwithacupunctureusingsuperﬁcialneedleinsertion
(SNI). Therefore, Wyon et al. [22] randomised women with
hot ﬂashes to either EA or superﬁcial needle insertion (SNI)
in the belief that EA would have a superior eﬀect on hot
ﬂashes compared to SNI. It was not, however, possible to
see any diﬀerences in eﬀect of treatment, although, in the
EA group, the reduction of hot ﬂashes was sustained for
a longer period of time after treatment than in the SNI
group. Frisk et al. [53] also randomised between EA and
MA in men castrated due to prostate cancer, but they
were unable to show any diﬀerences between the treatment
options regarding reduction in number of hot ﬂashes.
In a systematic review article [89], the eﬀectiveness of
acupuncture versus sham acupuncture for treatment of hot
ﬂashes was assessed. They found six randomised clinical
studies of acupuncture versus sham acupuncture but were
not able to show any diﬀerences between the eﬀects on
hot ﬂashes of acupuncture versus sham acupuncture. They
concluded, however, that the sample was too small and
that diﬀerent types of sham-acupuncture were used in the
diﬀerent studies [89].
It is of course of great interest and importance to ﬁnd
out if acupuncture would aﬀect other climacteric symptoms
than the hit ﬂashes. There are, however, to our knowledge
no studies on the eﬀects of acupuncture on, for example,
excessive sweating, anxiety, or other climacteric disorders as
primary outcome.
4. Calcitonin Gene-RelatedPeptide(CGRP)
CGRP is a 37-amino-acid neuropeptide, found predomi-
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verypotentvasodilatoroftheskinandmicrovasculature[90]
and plays an important role in neurogenic vasodilation of
the skin [91]. It can potentiate both acetylcholine-mediated
vasodilation and sweating [92]. CGRP has cardiovascular
eﬀects, proinﬂammatory actions, and metabolic eﬀects [93]
and often coexists with other peptides in sensory aﬀerents,
for example, substance P (SP), cholecystokinin, and dynor-
phin. Studies indicate that CGRP possibly plays a role in the
transmission of nociception in the rat spinal cord, but the
exact interactions with other nociceptive neurotransmitters
in the spinal cord, such as SP, glutamate, and opioids are
unknown [94]. Neuropeptides in the skin are synthesised
and released predominantly by a subpopulation of small
unmyelinated aﬀerent neurons (C-ﬁbers) designated as C-
polymodal nociceptors, which represent about 70% of all
cutaneous C-ﬁbres and, to a far smaller extent, by small
myelinated Aδ-ﬁbres [95]. Two forms of CGRP have thus
far been isolated, CGRP-α and CGRP-β.C G R P - α occurs
primarily in sensory neurons, whereas enteric neurons
mainlycontainCGRP-β.CGRP -αandCGRP-β aresuggested
to be regulated diﬀerently, and they probably act through
diﬀerent receptor subtypes [94]. Two receptor subtypes,
CGRP1 and CGRP2, have been identiﬁed that are speciﬁc
plasma membrane receptors. These are G-protein coupled
and are able to activate adenylate cyclase and increase in
intracellularcAMPthataresuﬃcienttoexplainmanyoftheir
eﬀects [94, 96]. Other eﬀects are NO dependent [97].
A wide distribution of CGRP messenger RNA, CGRP
immunoreactive (IR) cell bodies, and nerve ﬁbers is seen
in the central nervous systems (CNS) of various species
including the rat, cat, and human. CGRP-positive cells are
alsofoundinvariousautonomicgangliabuttoalesserextent
in sympathetic principal neurones in the stellate and lumbar
sympathetic ganglia. Some of the neurones, which contain
both CGRP and vasoactive intestinal peptide (VIP), project
to the sweat glands in rats [94, 98, 99].
CGRP ﬁber terminals are heavily concentrated in the
dorsal horn of the rat spinal cord. The CGRP-containing
axons are largely unmyelinated or small diameter myelinated
ﬁbres and constitute almost 30% of the primary aﬀerent
axons of the major aﬀerent input to the superﬁcial laminae
of the dorsal horn [94]. It has been concluded that highly
concentrated CGRP in nerve terminals is supplied by axonal
transport from the neurone cell bodies [100].
4.1.CGRPandtheCardiovascularSystem. Microinjectionsof
CGRP into the central nucleus of the amygdala elicited an
increase in arterial blood pressure and heart rate in the rat
[94]. In rats, low-intensity spinal cord stimulation induces
cutaneous vasodilation that is possibly mediated by periph-
eral release of CGRP [101], which also increases the heart
rate and force of contraction of the heart [94]. In humans,
exogenously administered human α-CGRP showed vasodila-
tory action in the skin [25]. The vasodilation induced by
CGRP may be achieved through more than one mechanism.
In some tissues vasodilation correlates strongly with a rise in
cAMP that is independent of nitric oxide (NO). In contrast,
in other tissues (e.g., rat aorta), the eﬀect is suggested to be
NO-dependent via an NO-induced increase in cGMP [97].
Inmicrovasculardermalendothelialcells,CGRPandSPhave
been shown to induce the release of NO [102]. K+ channels
in arterial smooth muscle cells of rabbits are sometimes
involved in CGRP-mediatedvasodilation [94].Hence,CGRP
canactivatevarioustransductionsignallingpathwaysandthe
vasodilation involves multiple second messengers [94].
4.2. CGRP and Sweat Glands. In the eccrine sweat glands,
Zancanaro et al. [103] have found immunoreactivity for
CGRP in secretory cells, granulated cells, and to some
extent parietal cells. Immunoactivity of CGRP has also been
detected in human axons of sudomotor cholinergic nerves
stimulating eccrine sweat glands [104] where vasoactive
intestinal peptide (VIP) has been shown to coexist [99,
104]. It has previously been reported that CGRP and VIP
exert an inﬂuence on human sweating under physiological
conditions [101]. It was therefore suggested that CGRP-(and
SP-) containing neurones are involved in the local vasodi-
lation associated with increased sweat production [103].
Immunoreactivity for NO was seen in myoepithelial cells
(i.e., contractile cells within the sweat glands). The presence
of CGRP, SP, and NO suggests local function interactions
involving NO release, myoepithelial cell contraction, and
vasodilation in the sweat glands [103].
4.3. CGRP and the Thermoregulatory Center. CGRP, when
injected into the hypothalamus, can increase body tem-
perature [105–108]. A recent study has shown that it
decreases the rate of ﬁring of warm-sensitive neurons in the
thermoregulatory center, leading to hyperthermia [109]. It is
possible that both central and peripheral actions are relevant
for hot ﬂushes [110].
4.4. Relationship between Estrogens, CGRP, and the Opioid
System. CGRP-IR ﬁbers have been observed in the superﬁ-
cial layers of the spinal dorsal horn with lower numbers of
ﬁbersinthedeeperlaminaeofthespinalcord[111],thesame
location where Blomqvist et al. [112] found colocalisation
of estrogen receptor IR and preproenkephalin messen-
ger RNA expression. Estrogen injected subcutaneously in
ovariectomized female rats results in a rapid increase in
spinal cord enkephalin mRNA levels [113]. This suggests
that estrogen inﬂuences opioid/enkephalin expression in
the lower medulla and spinal cord (preferentially in the
superﬁcial layers) and may thereby exert a modulatory eﬀect
on sensory and nociceptive processing directly at the spinal
and medullary levels [112] especially of relevance when
studying pain.
Endogenous and exogenous opioids modulate the release
of the potent vasodilator CGRP at the spinal cord level
[114, 115]. Gonadal hormones inﬂuence the endogenous
opioid system [116]. In male castrated rats messenger RNA
for the opioid precursor pro-opiomelanocortin is increased
in the hypothalamus following testosterone and estradiol
supplementation [117]. It has also been shown that there
is a positive correlation between cerebrospinal β-endorphin
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and estrogen aﬀects hypothalamic β-endorphin activity in
rats [119].
In ovariectomised rats treated with estrogen (implanted
silastic capsule), CGRP immunoreactivity and methionine-
enkephalin immunoreactivity increased in the medial pre-
optic nucleus and the periventricular preoptic nucleus of
the hypothalamus [120]. These ﬁndings show a connection
between estrogens, enkephalins, and CGRP in the central
nervous system very close to the thermoregulatory center.
Thus, estrogens may aﬀect CGRP production and release
both directly and indirectly via opioids.
5.Acupunctureand CGRP
Since CGRP, like other neuropeptides, has a short half-life
in the circulation system [121] and is degraded by neutral
endopeptidase,tryptase,andchymase[122–124],muchofits
actioncannotbemeasuredintheblood,becausedegradation
products circulate in the blood. However, we suggest that
24-hour urinary measurement of CGRP is a more reliable
measurement of total amount of CGRP released into the
circulation. Wyon and coworkers found a higher 24 hour
urinary excretion of CGRP in women with vasomotor
symptoms compared to excretion observed three months
later after successful acupuncture therapy [22]. Twenty-four-
hourCGRPexcretioninurinewashigherinpostmenopausal
womenwithﬂashesthaninpostmenopausalwomenwithout
ﬂashes and in fertile women [30]. In contrast, in men
treated by castration due to prostate cancer, no changes were
seen in urinary 24-hour excretion of CGRP three months
after castration compared to before castration, neither in
the group as a whole nor in the men who developed hot
ﬂashes [125]. Men treated successfully for hot ﬂushes with
acupuncture did not display a change in their 24h urine
CGRP excretion statistically [53].
Borud and co-workers could not ﬁnd changes in CGRP
excretion during acupuncture therapy of hot ﬂashes, but
this study included no 24-hour measurements of CGRP and
was therefore not really suitable to answer the question if
acupuncture therapy for hot ﬂashes aﬀects CGRP [126].
6. Conclusions and Suggestions for the Future
The eﬀect of acupuncture on hot ﬂashes in women and
men [22, 48–53, 84] is probably multifactorial, and placebo-
controlled studies are diﬃcult to achieve, since there are so
many components to be controlled for [75]. In the studies
on acupuncture and hot ﬂashes, eﬀorts have been made
to control the needling components, but in most cases
no diﬀerence is seen between treatment groups whereas
the within-group changes are evident [22, 53]. According
to the hypothesis of the mechanisms of hot ﬂashes, any
intervention thatincreasesestrogen,endorphin, or serotonin
concentrations or decreases noradrenalin activity may be
expectedtoreducehotﬂashesinmenopausalwomen.Exoge-
nous estrogen seems to have an eﬀect on many systems [31],
probablyaﬀectingallneurotransmittersinvolved.Alternative
treatments for hot ﬂashes may aﬀect one or perhaps several
but not all of the systems involved; that is, acupuncture
aﬀects the β-endorphin levels [62] and also aﬀects serotonin
and noradrenalin activity in the central nervous system
[70, 71]. Theoretically, by combining diﬀerent alternative
treatments, for example, SSRI and acupuncture, a synergistic
eﬀectofthesetreatmentswouldappearwithabettereﬀecton
hot ﬂashes than any single treatment alternative would have
by itself—except from that induced by estrogen treatment.
Randomised studies are required to investigate this.
Whether or not acupuncture has a direct eﬀect on the
release of CGRP in peripheral nerve endings remains to be
investigated, and it is possible that other neurotransmitters,
such as substance P, neurokinin A, neuropeptide Y, and
adrenomedullin [110], are also involved in the pathogenesis
of hot ﬂashes. However, there is evidence that CGRP is
involved in hot ﬂashes in women and men with prostate
cancer [11, 26–29], and a suggested treatment could there-
fore include a CGRP antagonist. There are a number of
CGRP receptor antagonists in various stages of preclinical
or clinical development, all of which are intended to treat
acute episodes of migraine [127, 128]. Hopefully, these
may become available in the future and tried as treatment
alternatives for hot ﬂashes.
Recently, accumulating neuroimaging studies of humans
have shown that acupuncture can modulate a widely dis-
tributed brain network. For example, the hypothalamus
presented saliently intermittent activations during an fMRI
session, both during needling and a prolonged period there-
after[129].Thesenewtechniquesmayinthefuturebeableto
measure activity during hot ﬂashes and perhaps also make it
possible to study neurotransmitters involved in this process.
What the real eﬀect is of the needling component of
acupuncture on hot ﬂashes remains to be investigated. More
randomised trials are needed if this is to be investigated
satisfactorily, and in these not only the needling eﬀect must
be controlled for but also for the nonneedling components
as well as for other nonspeciﬁc components as described by
Langevin et al. [75].
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